clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Parotid Diseases D010305 1 associated lipids
Glossitis, Benign Migratory D005929 1 associated lipids
Achlorhydria D000126 1 associated lipids
Extensively Drug-Resistant Tuberculosis D054908 1 associated lipids
Sacroiliitis D058566 1 associated lipids
Pseudomyxoma Peritonei D011553 1 associated lipids
Eye Infections D015817 1 associated lipids
Upper Extremity Deep Vein Thrombosis D056824 1 associated lipids
Buruli Ulcer D054312 1 associated lipids
Gastritis, Hypertrophic D005758 1 associated lipids
Myxoma D009232 1 associated lipids
Tuberculosis, Spinal D014399 1 associated lipids
Hypoproteinemia D007019 1 associated lipids
Cutaneous Fistula D017577 1 associated lipids
Kleine-Levin Syndrome D017593 1 associated lipids
Granuloma, Plasma Cell D006104 1 associated lipids
Epilepsy, Partial, Motor D020938 1 associated lipids
Tuberculosis, Ocular D014392 1 associated lipids
Encephalomyelitis, Acute Disseminated D004673 1 associated lipids
Empyema, Tuberculous D004654 1 associated lipids
Euthyroid Sick Syndromes D005067 1 associated lipids
Immune Reconstitution Inflammatory Syndrome D054019 1 associated lipids
Serositis D012700 1 associated lipids
Iritis D007500 2 associated lipids
Parotid Neoplasms D010307 2 associated lipids
Still's Disease, Adult-Onset D016706 2 associated lipids
Monoclonal Gammopathy of Undetermined Significance D008998 2 associated lipids
IgA Deficiency D017098 2 associated lipids
Eye Injuries, Penetrating D015807 2 associated lipids
Chlamydial Pneumonia D061387 2 associated lipids
Leprosy, Lepromatous D015440 2 associated lipids
Discitis D015299 2 associated lipids
Iris Diseases D007499 2 associated lipids
Angiomatosis, Bacillary D016917 2 associated lipids
Tooth, Nonvital D019553 2 associated lipids
Tuberculosis, Avian D014379 2 associated lipids
Immunoproliferative Small Intestinal Disease D007161 2 associated lipids
Hyperemesis Gravidarum D006939 2 associated lipids
Cardiovascular Abnormalities D018376 2 associated lipids
Chromoblastomycosis D002862 2 associated lipids
Leprosy, Paucibacillary D056005 2 associated lipids
Typhoid Fever D014435 2 associated lipids
Soft Tissue Infections D018461 2 associated lipids
Empyema, Pleural D016724 2 associated lipids
Diphtheria D004165 2 associated lipids
Soft Tissue Injuries D017695 2 associated lipids
Mastoiditis D008417 2 associated lipids
Periodontal Abscess D010508 2 associated lipids
Cytomegalovirus Retinitis D017726 2 associated lipids
Duodenogastric Reflux D004383 2 associated lipids
Fusobacterium Infections D005674 3 associated lipids
Ecchymosis D004438 3 associated lipids
Hernia, Hiatal D006551 3 associated lipids
Conjunctivitis, Bacterial D003234 3 associated lipids
Keratoconjunctivitis D007637 3 associated lipids
Bartonella Infections D001474 3 associated lipids
Paronychia D010304 3 associated lipids
Leprosy, Borderline D015439 3 associated lipids
Cryptogenic Organizing Pneumonia D018549 3 associated lipids
Psychophysiologic Disorders D011602 3 associated lipids
Scrub Typhus D012612 3 associated lipids
Fractures, Open D005597 3 associated lipids
Barrett Esophagus D001471 3 associated lipids
Giardiasis D005873 3 associated lipids
Central Nervous System Protozoal Infections D020808 3 associated lipids
alpha 1-Antitrypsin Deficiency D019896 3 associated lipids
Eye Infections, Bacterial D015818 3 associated lipids
Conjunctival Neoplasms D003230 3 associated lipids
Empyema D004653 3 associated lipids
Tenosynovitis D013717 3 associated lipids
Pleuropneumonia D011001 3 associated lipids
Pityriasis Rosea D017515 3 associated lipids
Peptic Ulcer Perforation D010439 3 associated lipids
Ureteral Diseases D014515 3 associated lipids
Sporotrichosis D013174 3 associated lipids
Actinomycetales Infections D000193 4 associated lipids
Peptic Ulcer Hemorrhage D010438 4 associated lipids
Dermatitis, Phototoxic D017484 4 associated lipids
Pleural Diseases D010995 4 associated lipids
Rodent Diseases D012376 4 associated lipids
Parotitis D010309 4 associated lipids
Psittacosis D009956 4 associated lipids
Confusion D003221 4 associated lipids
Prurigo D011536 4 associated lipids
Lymphangitis D008205 4 associated lipids
Mycetoma D008271 4 associated lipids
Mycobacterium avium-intracellulare Infection D015270 4 associated lipids
Legionnaires' Disease D007877 4 associated lipids
Cysts D003560 4 associated lipids
Duodenitis D004382 4 associated lipids
Gastritis, Atrophic D005757 4 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Common Variable Immunodeficiency D017074 4 associated lipids
Esophagitis, Peptic D004942 4 associated lipids
Foot Diseases D005534 4 associated lipids
Chlamydophila Infections D023521 4 associated lipids
Ergotism D004881 4 associated lipids
Purpura, Thrombocytopenic, Idiopathic D016553 4 associated lipids
Ureaplasma Infections D016869 5 associated lipids
Dyspepsia D004415 5 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Kasai C et al. Changes in plasma ghrelin and leptin levels in patients with peptic ulcer and gastritis following eradication of Helicobacter pylori infection. 2016 BMC Gastroenterol pmid:27716077
Patton PH et al. Anti-tuberculous therapy for maintenance of remission in Crohn's disease. 2016 Cochrane Database Syst Rev pmid:27444319
D'Erme AM et al. Successful treatment of rosacea fulminans in a 59-year-old woman with macrolide antibiotics and prednisone. 2016 Int. J. Dermatol. pmid:27028670
Belz D et al. Mycobacterium marinum infection initially diagnosed as metastatic Crohn's disease. 2016 J Eur Acad Dermatol Venereol pmid:25510444
Vannarath S et al. Antibiotic Resistant Pattern of Helicobacter Pylori Infection Based on Molecular Tests in Laos. 2016 Asian Pac. J. Cancer Prev. pmid:26838225
Yoon H et al. Effects of N-acetylcysteine on First-Line Sequential Therapy for Helicobacter pylori Infection: A Randomized Controlled Pilot Trial. 2016 Gut Liver pmid:26347514
Jenkins H et al. Effect of Multiple Oral Doses of the Potent CYP3A4 Inhibitor Clarithromycin on the Pharmacokinetics of a Single Oral Dose of Vonoprazan: A Phase I, Open-Label, Sequential Design Study. 2017 Clin Drug Investig pmid:27928738
Takemoto Y et al. Disseminated Mycobacterium scrofulaceum Infection in an Immunocompetent Host. 2017 Intern. Med. pmid:28717096
Alba C et al. Antibiotic resistance in Helicobacter pylori. 2017 Curr. Opin. Infect. Dis. pmid:28704226
Mishima E et al. Acute Kidney Injury from Excessive Potentiation of Calcium-channel Blocker via Synergistic CYP3A4 Inhibition by Clarithromycin Plus Voriconazole. 2017 Intern. Med. pmid:28674358
Sun W et al. Synergistic drug combination effectively blocks Ebola virus infection. 2017 Antiviral Res. pmid:27890675
Shimoyama T et al. Randomized Trial Comparing Esomeprazole and Rabeprazole in First-line Eradication Therapy for Helicobacter pylori Infection based on the Serum Levels of Pepsinogens. 2017 Intern. Med. pmid:28674348
Hung IFN et al. Efficacy of Clarithromycin-Naproxen-Oseltamivir Combination in the Treatment of Patients Hospitalized for Influenza A(H3N2) Infection: An Open-label Randomized, Controlled, Phase IIb/III Trial. 2017 Chest pmid:27884765
Ustundag GH et al. The Effects of Synbiotic " B94 plus Inulin" Addition on Standard Triple Therapy of Eradication in Children. 2017 Can J Gastroenterol Hepatol pmid:28656129
Peng X et al. Gastric Juice-Based Real-Time PCR for Tailored Treatment: A Practical Approach. 2017 Int J Med Sci pmid:28638276
Ozturk O et al. Therapeutic success with bismuth-containing sequential and quadruple regimens in Helicobacter pylori eradication. 2017 Arab J Gastroenterol pmid:28601610
Alirezaei A et al. Helicobacter pylori Eradication With Levofloxacin or Clarithromycin in Dialysis Versus Nonuremic Patients. 2017 Iran J Kidney Dis pmid:28575885
Varma MV et al. Transporter-Mediated Hepatic Uptake Plays an Important Role in the Pharmacokinetics and Drug-Drug Interactions of Montelukast. 2017 Clin. Pharmacol. Ther. pmid:27648490
Huet D et al. [Pulmonary infection with Mycobacterium malmoense. Difficulties in diagnosis and treatment]. 2017 Rev Mal Respir pmid:27639948
El Haj C et al. The anti-biofilm effect of macrolides in a rat model of S. aureus foreign-body infection: Might it be of clinical relevance? 2017 Med. Microbiol. Immunol. pmid:27639707
Jia L et al. Synthesis and antibacterial evaluation of novel 11-O-carbamoyl clarithromycin ketolides. 2017 Bioorg. Med. Chem. Lett. pmid:28711353
Seyama S et al. Emergence and molecular characterization of Haemophilus influenzae harbouring mef(A). 2017 J. Antimicrob. Chemother. pmid:27999037
Zerbetto De Palma G et al. Occurrence of Mutations in the Antimicrobial Target Genes Related to Levofloxacin, Clarithromycin, and Amoxicillin Resistance in Helicobacter pylori Isolates from Buenos Aires City. 2017 Microb. Drug Resist. pmid:27391421
Legendre T et al. [Antibiomania: Think of the manic syndrome secondary to antibiotic therapy]. 2017 Encephale pmid:27178256
Choi HS et al. Peritoneal Dialysis-Related Peritonitis Caused by Microbacterium paraoxydans. 2017 Jpn. J. Infect. Dis. pmid:27169951
Serrano CA et al. Helicobacter pylori-Clarithromycin Resistance in Symptomatic Pediatric Patients in a High Prevalence Country. 2017 J. Pediatr. Gastroenterol. Nutr. pmid:27159208
Abadi ATB Resistance to clarithromycin and gastroenterologist's persistence roles in nomination for Helicobacter pylori as high priority pathogen by World Health Organization. 2017 World J. Gastroenterol. pmid:29085187
Pastukh N et al. GenoType® HelicoDR test in comparison with histology and culture for Helicobacter pylori detection and identification of resistance mutations to clarithromycin and fluoroquinolones. 2017 Helicobacter pmid:29058343
Tognetti L et al. Bullous impetigo during interstitial pneumonitis. 2017 G Ital Dermatol Venereol pmid:29050448
Chen MJ et al. Impact of amoxicillin resistance on the efficacy of amoxicillin-containing regimens for Helicobacter pylori eradication: analysis of five randomized trials. 2017 J. Antimicrob. Chemother. pmid:28961996
Kim SY et al. Helicobacter pylori eradication rates of concomitant and sequential therapies in Korea. 2017 Helicobacter pmid:28940815
Souto Filho JTD et al. Long-term complete remission of primary gastric plasmacytoma following endoscopic resection. 2017 Ann. Hematol. pmid:28315923
Antonakos N et al. Decreased cytokine production by mononuclear cells after severe gram-negative infections: early clinical signs and association with final outcome. 2017 Crit Care pmid:28274246
Koratala A et al. Exit Site Infection in Peritoneal Dialysis; Need for Follow-Up on Cultures Despite Clinical Improvement. 2017 Blood Purif. pmid:28268216
Lin CM et al. Is ionizing radiation a risk factor to diffuse panbronchiolitis? 2017 QJM pmid:28069906
de Ávila BE et al. Micromotor-enabled active drug delivery for in vivo treatment of stomach infection. 2017 Nat Commun pmid:28814725
Zhang D et al. Berberine containing quadruple therapy for initial Helicobacter pylori eradication: An open-label randomized phase IV trial. 2017 Medicine (Baltimore) pmid:28796053
Fraser AG Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori. 2017 Aliment. Pharmacol. Ther. pmid:28776748
Jung YS et al. Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori-authors' reply. 2017 Aliment. Pharmacol. Ther. pmid:28776746
Makihara K et al. Clarithromycin co-administration does not increase irinotecan (CPT-11) toxicity in colorectal cancer patients. 2017 Cancer Chemother. Pharmacol. pmid:28711984
Tanabe H et al. Efficacy of Vonoprazan-Based Triple Therapy for Helicobacter pylori Eradication: A Multicenter Study and a Review of the Literature. 2017 Dig. Dis. Sci. pmid:28664410
Fohner AE et al. PharmGKB summary: Macrolide antibiotic pathway, pharmacokinetics/pharmacodynamics. 2017 Pharmacogenet. Genomics pmid:28146011
Iwayama K et al. Long-term treatment of clarithromycin at a low concentration improves hydrogen peroxide-induced oxidant/antioxidant imbalance in human small airway epithelial cells by increasing Nrf2 mRNA expression. 2017 BMC Pharmacol Toxicol pmid:28235416
Komiya K et al. Clarithromycin attenuates IL-13-induced periostin production in human lung fibroblasts. 2017 Respir. Res. pmid:28219384
Sakurai K et al. Comparative study: Vonoprazan and proton pump inhibitors in eradication therapy. 2017 World J. Gastroenterol. pmid:28216974
Awan S et al. Is clarithromycin a potential treatment for cachexia in people with lung cancer? A feasibility study. 2017 Lung Cancer pmid:28213005
Su J et al. Efficacy of 1st-line bismuth-containing quadruple therapies with levofloxacin or clarithromycin for the eradication of Helicobacter pylori infection: A 1-week, open-label, randomized trial. 2017 Medicine (Baltimore) pmid:28207505
Branquinho D et al. Levofloxacin or Clarithromycin-based quadruple regimens: what is the best alternative as first-line treatment for Helicobacter pylori eradication in a country with high resistance rates for both antibiotics? 2017 BMC Gastroenterol pmid:28202013
Inukai K et al. Effect of gel formation on the dissolution behavior of clarithromycin tablets. 2017 Int J Pharm pmid:28196716
Miftahussurur M et al. Clarithromycin-Based Triple Therapy is Still Useful as an Initial Treatment for Infection in the Dominican Republic. 2017 Am. J. Trop. Med. Hyg. pmid:28193745